Nuplazid

Active Ingredient(s): Pimavanserin
FDA Approved: * April 29, 2016
Pharm Company: * ACADIA PHARMACEUTICALS INC
Category: Antipsychotic

Pimavanserin (ACP-103; BVF-036), sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder.[3] Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.[4] Contents 1 Pharmacology 1.1 Pharmacodynamics 2 History 2.1 Devel... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nuplazid 10 mg Oral Tablet, Coated

NDC: 63090-100

Labeler:

Acadia Pharmaceuticals Inc

Nuplazid 17 mg Oral Tablet, Coated

NDC: 63090-170

Labeler:

Acadia Pharmaceuticals Inc

Nuplazid 34 mg Oral Capsule

NDC: 63090-340

Labeler:

Acadia Pharmaceuticals Inc